11:16 AM Aegerion (AEGR +6.6%) continues its uptrend, with the stock close to breaking out of a trading range that has persisted since 2011. The stock popped yesterday in reaction to an FDA staff report on its cholesterol drug lomitapide, and has ramped up nearly 35% since Friday in anticipation of its release.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.